← Back to All US Stocks

LMRI Stock Analysis 2026 - Lumexa Imaging Holdings, Inc. AI Rating

LMRI Nasdaq Services-Medical Laboratories DE CIK: 0002071288
Recently Updated • Analysis: Apr 12, 2026 • SEC Data: 2026-04-12
HOLD
15% Conf
Pending
Analysis scheduled

📊 LMRI Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: HOLD with 15% confidence

Is LMRI a Good Investment? Thesis Analysis

Claude

Unable to conduct fundamental analysis due to absence of financial data across all major metrics (revenue, profitability, balance sheet, cash flow). The lack of recent financial transparency and data availability is a material concern for investors despite company's medical laboratory sector positioning.

Why Buy LMRI? Key Strengths

Claude
  • + Recent insider Form 4 filings indicate management engagement
  • + Nasdaq-listed company in healthcare services sector
  • + Medical laboratory services operate in recurring revenue environment

LMRI Investment Risks to Consider

Claude
  • ! No financial data available - complete lack of transparency
  • ! Data freshness marked as 'None' suggesting stale or missing SEC filings
  • ! Unable to assess profitability, solvency, or operational performance
  • ! Potential company distress, delisting risk, or filing non-compliance

Key Metrics to Watch

Claude
  • * Quarterly revenue and net income recognition
  • * Current ratio and working capital position
  • * Operating cash flow generation and free cash flow

LMRI Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

LMRI Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

LMRI vs Healthcare Sector

How Lumexa Imaging Holdings, Inc. compares to Healthcare sector averages

Net Margin
LMRI 0.0%
vs
Sector Avg 12.0%
LMRI Sector
ROE
LMRI 0.0%
vs
Sector Avg 15.0%
LMRI Sector
Current Ratio
LMRI 0.0x
vs
Sector Avg 2.0x
LMRI Sector
Debt/Equity
LMRI 0.0x
vs
Sector Avg 0.6x
LMRI Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is LMRI Overvalued or Undervalued?

Based on fundamental analysis, Lumexa Imaging Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

LMRI Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

LMRI Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

LMRI SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for Lumexa Imaging Holdings, Inc. (CIK: 0002071288)

📋 Recent SEC Filings

Date Form Document Action
Apr 9, 2026 8-K d81221d8k.htm View →
Mar 30, 2026 10-K lmri_10k_2025.htm View →
Mar 26, 2026 8-K d138307d8k.htm View →
Mar 2, 2026 8-K d40982d8k.htm View →
Feb 27, 2026 4 xslF345X05/ownership.xml View →

Frequently Asked Questions about LMRI

What is the AI rating for LMRI?

Lumexa Imaging Holdings, Inc. (LMRI) has an AI rating of HOLD with 15% confidence, based on fundamental analysis of SEC EDGAR filings.

What are LMRI's key strengths?

Claude: Recent insider Form 4 filings indicate management engagement. Nasdaq-listed company in healthcare services sector.

What are the risks of investing in LMRI?

Claude: No financial data available - complete lack of transparency. Data freshness marked as 'None' suggesting stale or missing SEC filings.

What is LMRI's revenue and growth?

Lumexa Imaging Holdings, Inc. reported revenue of N/A.

Does LMRI pay dividends?

Lumexa Imaging Holdings, Inc. does not currently pay dividends.

Where can I find LMRI SEC filings?

Official SEC filings for Lumexa Imaging Holdings, Inc. (CIK: 0002071288) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is LMRI's EPS?

Lumexa Imaging Holdings, Inc. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is LMRI a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Lumexa Imaging Holdings, Inc. has a HOLD rating with 15% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is LMRI stock overvalued or undervalued?

Valuation metrics for LMRI: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy LMRI stock in 2026?

Our dual AI analysis gives Lumexa Imaging Holdings, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is LMRI's free cash flow?

Lumexa Imaging Holdings, Inc.'s operating cash flow is N/A, with capital expenditures of N/A.

How does LMRI compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 12, 2026 | Data as of: 2026-04-12 | Powered by Claude AI